ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2026
Incidence of P200 pemphigoid: A nationwide study.
Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Incidence of P200 pemphigoid: A nationwide study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Case Report: Dupilumab as a steroid-sparing therapeutic option in refractory anti-p200 pemphigoid: real-world effectiveness in a patient with significant comorbidities.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnti-p200 pemphigoid (P200) is a rare subepidermal autoimmune blistering disease (AIBD) related to anti-laminin γ1 autoantibodies (Abs). It has been recently reported that laminin β4 was frequently recognized by sera from patients with P200.
objectivesTo evaluate the incidence of P200 in France using a new recombinant anti-laminin β4 serological assay.
methodsThis multicentre retrospective study was conducted in the Immunology Laboratory of the French reference centre for AIBD from January 2018 to March 2023. Sera suspected of corresponding to P200 were tested using the new anti-LAMB4 cell-based immunoassay (CBIA) and/or immunoblotting (IB) on dermal extract. The incidence of P200 was then estimated based on its incidence rate relative to those of BP and pemphigus over the same period.
results116 patients with sera labelling the dermal side of salt-split skin by IIF and negative for other junctional AIBD were recorded. Among them, 23 patients' sera had already been tested positive for P200 by dermal IB. Thus, 93 patients' sera were tested with both the anti-LAMB4 CBIA and IB: 85 were positive with the CBIA (91%) vs. 44 with IB (47%, p < 0.0001). Only two were positive with IB alone. Overall, 110 patients had anti-p200 Abs. Subsequently, we compared the frequency of serological detection of P200 to that of BP and pemphigus based on data from centres that exhaustively submitted their sera to our reference laboratory. According to the incidence of BP and pemphigus in France (21.7 and 1.85 cases per million inhabitants per year, respectively), the incidence of P200 was estimated to range from 0.23 to 0.83 cases per million inhabitants per year. This corresponds to approximately 16-57 new cases annually in France, which is approximately 2- to 4-fold more frequent than epidermolysis bullosa acquisita.
conclusionsThis study shows that P200 may be much more frequent than initially estimated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.